Aggressive peripheral CD70-positive t-cell lymphoma associated with severe chronic active EBV infection

Pediatric Blood and Cancer

Volumn 59, Issue 4, 2012, Pages 758-761

  Shaffer, Donald R ^a,b   Sheehan, Andrea M ^b   Yi, Zhongzhen ^a,b   Rodgers, Cheryl C ^a,b   Bollard, Catherine M ^a,b   Brenner, Malcolm K ^a,b   Rooney, Cliona M ^a,b   Heslop, Helen E ^a,b   Gottschalk, Stephen ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CD70; EBV; Immunotherapy; Lymphoma

Indexed keywords

CD4 ANTIGEN; CD70 ANTIGEN; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; METHYLPREDNISOLONE; PREDNISONE; VIRUS DNA;

ARTICLE; CASE REPORT; CERVICAL LYMPHADENOPATHY; CHILD; CHRONIC ACTIVE EPSTEIN BARR VIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEVER; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; MALIGNANT TRANSFORMATION; MYELOABLATIVE CONDITIONING; PANCYTOPENIA; PERIPHERAL T CELL LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT INFECTION; REED STERNBERG CELL; T CELL LYMPHOMA; T LYMPHOCYTE RECEPTOR GENE; VIRUS DETECTION; VIRUS GENOME; VIRUS LOAD;

ANTIGENS, CD70; CHILD, PRESCHOOL; CHRONIC DISEASE; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL; MALE; T-LYMPHOCYTES;

EID: 84864944376     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23352     Document Type: Article

References (19)

1. Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003; 187: 527-533.
2. Cohen JI, Kimura H, Nakamura S, et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 2009; 20: 1472-1482.
3. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 98: 280-286.
4. Ishihara S, Okada S, Wakiguchi H, et al. Clonal lymphoproliferation following chronic active Epstein-Barr virus infection and hypersensitivity to mosquito bites. Am J Hematol 1997; 54: 276-281.
5. Ohshima K, Suzumiya J, Sugihara M, et al. Clinicopathological study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome. Pathol Int 1998; 48: 934-943.
6. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007; 110: 2838-2845.
7. Hintzen RQ, Lens SM, Beckmann MP, et al. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol 1994; 152: 1762-1773.
8. Shaffer DR, Savoldo B, Yi Z, et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 2011; 117: 4304-4314.
9. Ohshima K, Kimura H, Yoshino T, et al. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: Overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int 2008; 58: 209-217.
10. Quintanilla-Martinez L, Kimura H, Jaffe ES. EBV-positive lymphoproliferative disorders of childhood. In. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008; p 278-280.
11. Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant 2011; 46: 77-783.
12. Gotoh K, Ito Y, Shibata-Watanabe Y, et al. Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. Clin Infect Dis 2008; 46: 1525-1534.
13. Okamura T, Hatsukawa Y, Arai H, et al. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet 2000; 356: 223-224.
14. Cohen JI, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: A 28-year experience in the United States. Blood 2011; 117: 5835-5849.
15. Okamura T, Kishimoto T, Inoue M, et al. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant 2003; 31: 105-111.
16. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol 2010; 22: 251-257.
17. McEarchern JA, Oflazoglu E, Francisco L, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2007; 109: 1185-1192.
18. Baba M, Okamoto M, Hamasaki T, et al. Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-cell lines and adult T-cell leukemia cells. J Virol 2008; 82: 3843-3852.
19. Israel BF, Gulley M, Elmore S, et al. Anti-CD70 antibodies: A potential treatment for EBV+ CD70-expressing lymphomas. Mol Cancer Ther 2005; 4: 2037-2044.